Very late-onset membranous nephropathy secondary to alemtuzumab in a patient with multiple sclerosis
Nefropatía membranosa muy tardía secundaria a alemtuzumab en paciente con esclerosis múltiple
Área salud
Recommendations for the critical reading of clinical trials on disease-modifying drugs for multiple sclerosis
Introduction In recent years there has been an increase in the number of disease-modifying drugs (DMDs) approved for multiple sclerosis (MS). The evidence of their safety and efficacy has been obtained through several phase III […]
Área salud
Impact of COVID-19 on physiotherapy for patients with multiple sclerosis in Spain: Adaptation and challenges in the implementation of telerehabilitation
Introduction The COVID-19 pandemic, declared in March 2020, had a profound impact on health services in Spain, especially on physiotherapy for people with multiple sclerosis (PwMS). The health reorganization forced the suspension of rehabilitation services, […]
Área salud
Inflammatory bowel disease and multiple sclerosis
Introduction Inflammatory bowel disease (IBD), which mainly includes Crohn’s disease and ulcerative colitis, is characterised by chronic inflammation in the gastrointestinal tract, triggered and perpetuated by an altered immune response. An association has been established […]